International: +1-347-960-6455
Myasthenia Gravis (MG) Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers

According to a new research report Myasthenia Gravis (MG) Therapeutics Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, MG therapeutics currently exhibits a proliferating pipeline with 15+ therapeutic candidates.

MG Therapeutics Pipeline Insights

MG is a neuromuscular disorder, which weakens muscles by decreasing number of acetylcholine receptors at the neuromuscular junction. The disease becomes prominent during adulthood; but symptoms can be observed at any age. People suffering from MG show weakness and drooping of the eyelids, resulting in double vision and excessive fatigue caused after physical work. The disease can be detected by physical examination and diagnostic imaging tests.

Soliris by Alexion Pharmaceuticals Inc. is the only U.S. Food and Drug Administration (USFDA) approved therapeutic drug for the treatment of MG.

Insights into Pipeline Segments

According to the research findings, majority of pipeline drug candidates are being developed for intravenous route of administration. In this route of administration, entire administered dose reaches the systemic circulation immediately, which increases the bioavailability of drug. Administration of therapeutics for MG through intravenous route has shown promising results in clinical studies.

Positive Clinical Results are Expected to Drive the MG Therapeutics Pipeline

Companies that are involved in developing therapeutics for MG have shown positive clinical results in various phases of drug development. For instance, in December 2018, Ra Pharmaceuticals Inc. announced positive data of phase II trial of zilucoplan for the treatment of patients with MG. The results of the study concluded that treatment with zilucoplan has a favorable safety and tolerability profile, consistent with previously-completed phase I and phase II studies. The majority of adverse events (AEs) reported were mild and not considered by investigators to be related to study drug. There were no serious AEs observed related to treatment with zilucoplan.

Browse Detailed Report at:

Global Market for MG Therapeutics is Expected to Increase Statistically in the next 10 years

Soliris is the only drug used for the treatment of MG. Therefore, with the emergence of late- and mid-stage pipeline products in the market, the overall MG therapeutics market is expected to grow significantly in the upcoming years.

Momenta Pharmaceuticals Inc., Immunovant Inc., Catalyst Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., ARGENX SE, GlaxoSmithKline PLC, Toleranzia AB, and Ra Pharmaceuticals Inc. are some of the key players involved in the development of therapeutic drugs indicated for the treatment of MG.

MG Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of MG. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the MG therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to MG.